CompletedNCT00297388

A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder

Medication studyAges 18–70

The study in practice

Understand this study

This study was for people with schizophrenia. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.

Study clarity

Study start dateNot clearly listed

Recruitment status: Completed
Enrollment listed in the registry: 40
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: Not clearly listed
Age range: From 18 Years to 70 Years
Official registry ID: NCT00297388
Official title: Show the full official title
A 52-wk Prospective, Randomized, Double-blind, Multicenter Study of Relapse Following Transition From Oral Antipsychotic Medication to 2 Different Doses (25 or 50 mg Every 2 Wks) of Risperidone Long-acting Microspheres (Risperdal� CONSTA�) in Adults With Schizophrenia or Schizoaffective Disorder

Completed

Locations not listed

FAQ

Who is behind this study?

The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Risperidone, long-acting injectable.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.

Explore other studies

Explore HopeStage studies by mental health topic and refine the results to suit your situation.